ASN-004 is under clinical development by Asana BioSciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASN-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ASN-004 overview

ASN-004 is under development for the treatment of solid tumors including breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, and head and neck squamous cell carcinoma. The drug candidate is an antibody-drug conjugate (ADC) which acts by targeting 5T4-oncofetal glycoprotein. It is developed based on fleximer linker (Dolaflexin) technology.

It was under development for the treatment of gastric cancer and cervical epidermoid tumor.

Asana BioSciences overview

Asana BioSciences (Asana) is a clinical-stage biopharmaceutical company that offers discovery and development of novel targeted investigational medicines. The company’s early-stage drug candidates include ASN001, ASN002, ASN003, ASN004, ASN005 and others. It develops drugs in therapeutic areas of oncology, urology, inflammation, respirator and, pain management, among others. Asana’s lead candidates are in phase I and II clinical studies and other molecules at late stages of preclinical development. The company works in collaboration with research institutions and biotechnology companies. Asana is headquartered in Lawrenceville, New Jersey, the US

For a complete picture of ASN-004’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.